Jade Clarson

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.

Journal: Blood neoplasia
Published: November 03, 2023

Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.

Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.

Journal: British journal of haematology
Published: April 22, 2023

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.

Journal: Blood advances
Published: August 31, 2022

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.

Journal: Nature communications
Published: May 27, 2020

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.

Journal: British journal of haematology
Published: March 06, 2020

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

Journal: British journal of haematology
Published: March 28, 2019

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Journal: Leukemia research
Published: November 17, 2016

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Journal: Blood
Published: October 16, 2016
Showing 1-8 of 8

Last Updated: 09/26/2026